Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Cytosorbents's Business Segments
Cytosorbents's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Single reportable segment
Total Revenue
$ 8
Regions Reported
1
Revenue Share by Reportable Segment - Q1 FY2026
- Single reportable segment0%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single reportable segment | $ 9 | - |
Revenue Share by Region - Q1 FY2026
- All other countries75.4%
Revenue by Geographic Region - Q1 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| All other countries | $ 6 | 75.4% |
Description of Cytosorbents
Cytosorbents Corporation is a leading biomedical company specializing in the development of advanced medical devices designed to remove harmful substances from the bloodstream. The company was founded in 1997 and is headquartered in Monmouth Junction, New Jersey.
Cytosorbents focuses on the development and commercialization of its proprietary technology called CytoSorb, a blood purification system that utilizes highly porous polymer beads to remove toxins, cytokines, and other harmful substances from the blood. These beads are designed to mimic the structure of human organs, allowing for optimal adsorption and filtration of a wide range of molecules.
The CytoSorb device is used in a variety of medical applications, including the treatment of critical care patients with conditions such as sepsis, acute respiratory distress syndrome (ARDS), COVID-19, and other conditions characterized by excessive inflammation and cytokine release. By removing these harmful substances from the bloodstream, CytoSorb aims to support the body's natural healing process and improve patient outcomes.
In addition to its flagship product CytoSorb, Cytosorbents Corporation also develops and markets other blood purification devices. This includes the VetResQ System, a veterinary version of the CytoSorb device for the treatment of critically ill animals, and HemoDefend, a product designed to remove contaminants from blood during transfusions.
The company has established a global presence, with distribution agreements and partnerships in over 60 countries around the world. It has received multiple regulatory approvals, including the CE Mark in Europe and the FDA Emergency Use Authorization (EUA) for the use of CytoSorb in COVID-19 patients in the United States.
Cytosorbents Corporation is committed to ongoing research and development, continuously working to enhance its technologies and expand its product portfolio. The company collaborates with leading academic institutions and medical centers to conduct clinical trials and further validate the efficacy and safety of its products.
In terms of financial performance, Cytosorbents Corporation has experienced significant growth in recent years. Its revenue has steadily increased, driven by growing demand for its products, expanding market presence, and successful commercialization efforts. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol CTSO.
Overall, Cytosorbents Corporation is a dynamic and innovative biomedical company focused on improving patient outcomes through the development of advanced blood purification technologies. With its flagship product CytoSorb and a strong presence in the global market, the company continues to make significant contributions to the field of critical care medicine.
Cytosorbents focuses on the development and commercialization of its proprietary technology called CytoSorb, a blood purification system that utilizes highly porous polymer beads to remove toxins, cytokines, and other harmful substances from the blood. These beads are designed to mimic the structure of human organs, allowing for optimal adsorption and filtration of a wide range of molecules.
The CytoSorb device is used in a variety of medical applications, including the treatment of critical care patients with conditions such as sepsis, acute respiratory distress syndrome (ARDS), COVID-19, and other conditions characterized by excessive inflammation and cytokine release. By removing these harmful substances from the bloodstream, CytoSorb aims to support the body's natural healing process and improve patient outcomes.
In addition to its flagship product CytoSorb, Cytosorbents Corporation also develops and markets other blood purification devices. This includes the VetResQ System, a veterinary version of the CytoSorb device for the treatment of critically ill animals, and HemoDefend, a product designed to remove contaminants from blood during transfusions.
The company has established a global presence, with distribution agreements and partnerships in over 60 countries around the world. It has received multiple regulatory approvals, including the CE Mark in Europe and the FDA Emergency Use Authorization (EUA) for the use of CytoSorb in COVID-19 patients in the United States.
Cytosorbents Corporation is committed to ongoing research and development, continuously working to enhance its technologies and expand its product portfolio. The company collaborates with leading academic institutions and medical centers to conduct clinical trials and further validate the efficacy and safety of its products.
In terms of financial performance, Cytosorbents Corporation has experienced significant growth in recent years. Its revenue has steadily increased, driven by growing demand for its products, expanding market presence, and successful commercialization efforts. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol CTSO.
Overall, Cytosorbents Corporation is a dynamic and innovative biomedical company focused on improving patient outcomes through the development of advanced blood purification technologies. With its flagship product CytoSorb and a strong presence in the global market, the company continues to make significant contributions to the field of critical care medicine.
Cytosorbents Corporation is a biotechnology company that specializes in developing and commercializing innovative blood purification therapies. The companys focus is on products that can remove harmful substances from the bloodstream to improve patient outcomes in critical care settings. Below is an extensive overview of the segments, products, and services that Cytosorbents Corporation offers.
Segments
1. Critical Care: This segment encompasses therapies that target life-threatening conditions, particularly in hospital settings. Cytosorbents is primarily focused on managing sepsis, organ failure, and other critical illnesses.
2. Cardiothoracic Surgery: In this area, the company develops products aimed at improving patient outcomes during and after cardiac surgeries. The focus is on mitigating the inflammatory response associated with surgery.
3. Regenerative Medicine: This segment may explore applications of blood purification technologies to enhance tissue healing and regeneration after injury or surgery.
4. Transfusion Medicine: Products that can potentially cross over into transfusion practices to improve the safety and efficacy of blood products.
Products
1. CytoSorb®:
- This is the flagship product of Cytosorbents, designed for use in the intensive care unit and during cardiac surgeries.
- Mechanism: CytoSorb is an extracorporeal blood purification device that removes pro-inflammatory cytokines, toxins, and other blood-borne substances.
- Applications: Primarily used in patients with sepsis, cytokine storm syndrome (as seen in conditions like COVID-19), and other inflammatory conditions that can lead to organ failure.
2. Kantaro™:
- This is a collaborative product that accelerates the assessment and therapeutic action against viral infections.
- Though primarily focused on COVID-19, the technology may have broader implications in the future for other viral infections.
3. HemoDefend™:
- An emerging technology aimed at improving the quality and safety of blood transfusions.
- It targets the removal of various toxins and contaminants that can be present in donated blood products.
4. Other Pipeline Products:
- Cytosorbents is actively engaged in research and development to expand its product offerings. This may include new formulations or devices intended for various medical conditions that could benefit from blood purification.
Services
1. Clinical Trials and Research:
- Cytosorbents invests time and resources into clinical trials to validate the effectiveness and safety of its products.
- The company collaborates with hospitals and academic institutions to gather data that supports the clinical use of its technologies.
2. Education and Training:
- Providing educational resources and training to healthcare professionals is a significant aspect of Cytosorbents service.
- This includes workshops, seminars, and online resources to ensure clinicians understand how to properly use its products and the science behind blood purification.
3. Regulatory Support:
- The company offers regulatory support to help healthcare organizations navigate the complexities of introducing new therapies and products into clinical practice.
- This includes assistance with compliance concerning FDA regulations or CE marking in Europe.
4. Partnership Development:
- Cytosorbents often engages in partnerships with other companies, research institutions, and hospitals to explore new applications for its technology.
- These partnerships may lead to co-development of products and jointly funded research.
Summary
Cytosorbents Corporation has carved out a niche in the biotechnology sector focused on innovative blood purification therapies. Its main product, CytoSorb, shows promise in treating critical conditions exacerbated by inflammatory responses. The companys expansions into areas like transfusion medicine and regenerative therapies indicate its commitment to leveraging its core technology for broader applications. Furthermore, with a strong emphasis on clinical research, education, and strategic partnerships, Cytosorbents is positioned to enhance patient care in critical and surgical settings through its advanced medical technologies.
Segments
1. Critical Care: This segment encompasses therapies that target life-threatening conditions, particularly in hospital settings. Cytosorbents is primarily focused on managing sepsis, organ failure, and other critical illnesses.
2. Cardiothoracic Surgery: In this area, the company develops products aimed at improving patient outcomes during and after cardiac surgeries. The focus is on mitigating the inflammatory response associated with surgery.
3. Regenerative Medicine: This segment may explore applications of blood purification technologies to enhance tissue healing and regeneration after injury or surgery.
4. Transfusion Medicine: Products that can potentially cross over into transfusion practices to improve the safety and efficacy of blood products.
Products
1. CytoSorb®:
- This is the flagship product of Cytosorbents, designed for use in the intensive care unit and during cardiac surgeries.
- Mechanism: CytoSorb is an extracorporeal blood purification device that removes pro-inflammatory cytokines, toxins, and other blood-borne substances.
- Applications: Primarily used in patients with sepsis, cytokine storm syndrome (as seen in conditions like COVID-19), and other inflammatory conditions that can lead to organ failure.
2. Kantaro™:
- This is a collaborative product that accelerates the assessment and therapeutic action against viral infections.
- Though primarily focused on COVID-19, the technology may have broader implications in the future for other viral infections.
3. HemoDefend™:
- An emerging technology aimed at improving the quality and safety of blood transfusions.
- It targets the removal of various toxins and contaminants that can be present in donated blood products.
4. Other Pipeline Products:
- Cytosorbents is actively engaged in research and development to expand its product offerings. This may include new formulations or devices intended for various medical conditions that could benefit from blood purification.
Services
1. Clinical Trials and Research:
- Cytosorbents invests time and resources into clinical trials to validate the effectiveness and safety of its products.
- The company collaborates with hospitals and academic institutions to gather data that supports the clinical use of its technologies.
2. Education and Training:
- Providing educational resources and training to healthcare professionals is a significant aspect of Cytosorbents service.
- This includes workshops, seminars, and online resources to ensure clinicians understand how to properly use its products and the science behind blood purification.
3. Regulatory Support:
- The company offers regulatory support to help healthcare organizations navigate the complexities of introducing new therapies and products into clinical practice.
- This includes assistance with compliance concerning FDA regulations or CE marking in Europe.
4. Partnership Development:
- Cytosorbents often engages in partnerships with other companies, research institutions, and hospitals to explore new applications for its technology.
- These partnerships may lead to co-development of products and jointly funded research.
Summary
Cytosorbents Corporation has carved out a niche in the biotechnology sector focused on innovative blood purification therapies. Its main product, CytoSorb, shows promise in treating critical conditions exacerbated by inflammatory responses. The companys expansions into areas like transfusion medicine and regenerative therapies indicate its commitment to leveraging its core technology for broader applications. Furthermore, with a strong emphasis on clinical research, education, and strategic partnerships, Cytosorbents is positioned to enhance patient care in critical and surgical settings through its advanced medical technologies.